Related references
Note: Only part of the references are listed.Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Fangrong Yan et al.
CLINICAL CANCER RESEARCH (2017)
A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent
M. -K. Riviere et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2015)
Bayesian optimal interval designs for phase I clinical trials
Suyu Liu et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2015)
Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding
Peter F. Thall et al.
CLINICAL TRIALS (2014)
Bayesian Model Averaging Continual Reassessment Method for Bivariate Binary Efficacy and Toxicity Outcomes in Phase I Oncology Trials
Takashi Asakawa et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2014)
Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials With Delayed Outcomes
Ick Hoon Jin et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2014)
A Bayesian dose finding design for oncology clinical trials of combinational biological agents
Chunyan Cai et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2014)
An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials
Akihiro Hirakawa
STATISTICS IN MEDICINE (2012)
Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates
Peter F. Thall et al.
BIOMETRICS (2008)
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios
Guosheng Yin et al.
BIOMETRICS (2006)
An adaptive dose-finding design incorporating both toxicity and efficacy
Wei Zhang et al.
STATISTICS IN MEDICINE (2006)
Adaptive designs for dose-finding based on efficacy-toxicity response
V Dragalin et al.
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2006)
Dose-finding based on efficacy-toxicity trade-offs
PF Thall et al.
BIOMETRICS (2004)
The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes
TA Braun
CONTROLLED CLINICAL TRIALS (2002)
Perspectives on the development of a molecularly targeted agent
BJ Druker
CANCER CELL (2002)
Share Paper
